Victory Capital Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 30, 2024, concerns Victory Capital Holdings, Inc. ("Victory") and its proposed acquisition of Amundi Holdings US, Inc. ("Amundi US") from Amundi Asset Management S.A.S. The filing serves as a supplemental disclosure to the definitive proxy statement filed on September 6, 2024, in response to stockholder litigation and demand letters alleging material omissions regarding the transaction.
Key Financial Metrics and Transaction Terms
The filing does not report standard quarterly financial results (revenue, profit, cash flow) for the period ended September 30, 2024. Instead, it details the financial structure of the proposed Contribution:
- Consideration: Victory will issue shares representing 4.9% of its outstanding common stock and a new series of nonvoting convertible preferred stock to Amundi.
- Dilution: The aggregate issuance will represent 26.1% of Victory's fully diluted shares post-transaction.
- Valuation Analysis (PJT Partners):
- Victory Implied Value: Discounted Cash Flow (DCF) analysis yielded an implied equity value range of $34.75 to $47.75 per share (based on ~66.7 million fully diluted shares as of June 30, 2024).
- Amundi US Implied Value: DCF analysis yielded an implied equity value range of $950 million to $1,230 million.
- Comparable Multiples (CY2025E): Traditional Asset Managers median P/EPS was 9.6x; Multi-Boutiques median P/EPS was 7.2x.
- Advisory Fees: PJT Partners received $2.5 million upon delivery of its opinion. Upon closing, PJT is entitled to $1.5 million plus a portion of a $9.0 million discretionary performance fee.
Material Changes and Litigation Matters
The primary material event is the filing of two stockholder lawsuits in the Supreme Court of the State of New York on September 19, 2024 (Kent v. Victory Capital Holdings, Inc. and Lawrence v. Victory Capital Holdings, Inc.), alongside five demand letters. Plaintiffs allege the proxy statement was materially incomplete and misleading. In response, Victory voluntarily amended disclosures regarding:
- Financial Projections: Clarified that Victory and Amundi US projections were prepared as of June 2024 on a standalone basis without synergies.
- Valuation Methodology: Provided specific details on the DCF analysis inputs, including discount rates (11.5%-13.5% for Victory; 12.0%-14.0% for Amundi US) and exit multiples.
- Share Count: Specified the use of approximately 66.7 million fully diluted shares for valuation calculations.
Guidance, Outlook, and Risks
Management Commentary: Victory denies all allegations of wrongdoing and asserts the proxy statement complies with applicable laws. However, to avoid litigation delays, the company is providing supplemental disclosures. The Board continues to recommend a "FOR" vote on the transaction.
Transaction Timeline: The special meeting of stockholders to approve the transaction is scheduled for October 11, 2024. The supplemental disclosures do not alter the consideration or the meeting date.
Risks: The filing highlights risks that closing conditions may not be satisfied, the transaction may fail to close, and expected synergies may not be achieved. It also notes standard forward-looking statement risks regarding future business performance.
Investor Verification Checklist
- Verify the outcome of the stockholder special meeting scheduled for October 11, 2024.
- Monitor the status of the pending litigation (Kent and Lawrence) and any potential injunctions.
- Review the definitive proxy statement (filed September 6, 2024) in conjunction with this 8-K for full transaction details.
- Confirm the final share count and dilution impact upon closing of the Contribution.
- Assess the realization of the projected synergies and the accuracy of the standalone financial projections provided to the board.